Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70297 | 1.00 | MEN1 (0.61) | MEN1KMT2AALDH1A1GAAPKM | |
| SCHEMBL1763611 | 0.92 | MEN1 (0.58) | MEN1KMT2AALDH1A1GAAPKM | |
| SCHEMBL29938229 | 0.92 | MEN1 (0.58) | MEN1KMT2AALDH1A1GAAPKM | |
| SCHEMBL13596619 | 0.89 | SMN1; SMN2 (0.58) | MEN1KMT2AALDH1A1GAAPKM | |
| SCHEMBL1763613 | 0.89 | MEN1 (0.55) | MEN1KMT2AALDH1A1GAAPKM | |
| SCHEMBL23870561 | 0.89 | MEN1 (0.55) | MEN1KMT2AALDH1A1GAAPKM | |
| SCHEMBL31676628 | 0.89 | SMN1; SMN2 (0.58) | MEN1KMT2AALDH1A1GAAPKM | |
| SCHEMBL6849222 | 0.88 | MEN1 (0.71) | MEN1KMT2AALDH1A1GAAPKM | |
| SCHEMBL4988971 | 0.85 | SMN1; SMN2 (0.61) | MEN1KMT2AALDH1A1GAAPKM | |
| SCHEMBL70296 | 0.85 | MEN1 (0.58) | MEN1KMT2AALDH1A1GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719450-A2 | MODIFIED CAVEOLIN-1 PEPTIDE FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF | Rein Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4673477-A1 | CONDITIONALLY ACTIVE ANTI-EPCAM ANTIBODIES, ANTIBODY FRAGMENTS AND CONSTRUCTS INCORPORATING SAME | BioAtla, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4554605-A2 | MODIFIED CAVEOLIN-1 PEPTIDE FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF | Rein Therapeutics, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4522651-A1 | MULTICHAIN MULTITARGETING BISPECIFIC ANTIGEN-BINDING MOLECULES OF INCREASED SELECTIVITY | Amgen Research (Munich) GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| WO-2025029690-A1 | ENGINEERED IGA ANTIBODIES AND METHODS OF USE | TIGATX, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| WO-2024249565-A2 | MODIFIED CAVEOLIN-1 PEPTIDE FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF | LUNG THERAPEUTICS, LLC (US) | 2024-12-05 | — | — | WO | disclosed |
| US-12090211-B2 | Methods for preparing antibody drug conjugates | GENENTECH, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| WO-2024182645-A1 | CONDITIONALLY ACTIVE ANTI-EPCAM ANTIBODIES, ANTIBODY FRAGMENTS AND CONSTRUCTS INCORPORATING SAME | BIOATLA, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| EP-4347622-A1 | RECONSTITUTION AND USES OF FLAVIVIRUS EPITOPES | Ramot at Tel-Aviv University Ltd. (IL) | 2024-04-10 | — | — | EP | disclosed |
| EP-4337676-A1 | ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2023154916-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIOUS DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230233700-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | GENENTECH, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| EP-4135738-A2 | METHOD OF TREATING CORONAVIRUS INFECTIONS | Cohbar Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11547762-B2 | Methods for preparing antibody drug conjugates | GENENTECH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2022254433-A1 | RECONSTITUTION AND USES OF FLAVIVIRUS EPITOPES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022240757-A1 | ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS | ENTRADA THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022217037-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC LUNG DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022133361-A2 | POLYPEPTIDES, VACCINE COMPOSITIONS, AND USE THEREOF FOR INDUCING IMMUNE RESPONSE TO SARS-COV-2 IN PRIMATES | ZHANG KANG (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022096716-A2 | MULTITARGETING BISPECIFIC ANTIGEN-BINDING MOLECULES OF INCREASED SELECTIVITY | AMGEN INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022087224-A1 | METHOD OF TREATING FIBROSIS WITH A COMBINATION THERAPY | COHBAR, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233700-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | FCGRT, MSN, FCGR3B | MEN1 982/4885KMT2A 448/4885ALDH1A1 272/4885 |
| US-11547762-B2 | Methods for preparing antibody drug conjugates | FCGRT, MSN, FCGR3B | MEN1 982/4885KMT2A 448/4885ALDH1A1 272/4885 |
| US-12090211-B2 | Methods for preparing antibody drug conjugates | FCGRT, MSN, FCGR3B | MEN1 982/4885KMT2A 448/4885ALDH1A1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.